A new milestone of Hong Kong Pharmaceutical Journal

LAM, May



Editorial
HKPharm J Volume 30 (3), Sep-Dec-2023 (2024-02-19): P.63

We are thrilled to announce a significant milestone in the evolution of Hong Kong Pharmaceutical Journal. In February, we will embark on an exciting journey as we introduce the soft launch of our online website, marking a new chapter in our commitment to providing accessible scholarly content. With the rapid advancements in technology and the changing landscape of publishing, we recognize the need to adapt and embrace the opportunities presented to us. As we strive to cater to the diverse needs of our audience, we have made the decision to transition from a traditional hard copy format to an online platform. Starting from next issue (Volume 31, Number 1), Hong Kong Pharmaceutical Journal will be available online only.

 

In this issue on page 68, “Conversations with pharmacy leaders in Hong Kong – skills for success: lateral thinking, confidence & the three Rs” written by Chan Stephanie Nok-Yan et al., Prof. Ian Wong shares with us his thoughts and experiences to his success as a pharmacist, educator and researcher. Having had the opportunity to work alongside Prof. Wong for more than a decade, I have been fortunate enough to observe the embodiment of his "Three Rs" - Respect, Resilience, and Resoluteness - in his work. He is not only my superior, but also a sagacious mentor, an inspiration and a trusted confidant.

 

In the article authored by Tang Ho Yeung et al., titled "Safety and efficacy of high-potency statin in Chinese patients with established cardiovascular disease," featured on page 70, it was reported that high-intensity statins demonstrated a greater reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with acute coronary syndrome. However, these statins were associated with a higher incidence of adverse effects compared to lower-intensity statins. Interestingly, the study found that neither statin intensity nor LDL-C goal attainment had significant effects on the occurrence or time-to-event of efficacy outcomes.

 

As we venture into this fresh chapter, we wish to extend our heartfelt appreciation to our readership for their unwavering support over the years. Your continued support is truly invaluable as we embark on this exhilarating digital journey. We firmly believe that transitioning to our online platform will not only enrich your experience but also present new avenues for growth. Furthermore, I would like to seize this opportunity to express my deep gratitude to the dedicated members of our Editorial Committee. Their tireless commitment and diligence have been instrumental in curating each issue. Additionally, I extend my sincere thanks to all the authors who have wholeheartedly supported the Journal. Your contributions have been greatly appreciated.

 

As always, you may provide suggestions and give feedbacks on any aspect of the Journal by contacting me or other members of the Editorial Committee. We would very much like to hear your thoughts on any part of the Journal and how we can further develop the Journal. But most importantly, how we can make it more appealing to you, our valued readers.


2024-02-19 於2024月02月19日

We are thrilled to announce a significant milestone in the evolution of Hong Kong Pharmaceutical Journal. In February, we will embark on an exciting journey as we introduce the soft launch of our online website, marking a new chapter in our commitment to providing accessible scholarly content. With the rapid advancements in technology and the changing landscape of publishing, we recognize the need to adapt and embrace the opportunities presented to us. As we strive to cater to the diverse needs of our audience, we have made the decision to transition from a traditional hard copy format to an online platform. Starting from next issue (Volume 31, Number 1), Hong Kong Pharmaceutical Journal will be available online only.

 

In this issue on page 68, “Conversations with pharmacy leaders in Hong Kong – skills for success: lateral thinking, confidence & the three Rs” written by Chan Stephanie Nok-Yan et al., Prof. Ian Wong shares with us his thoughts and experiences to his success as a pharmacist, educator and researcher. Having had the opportunity to work alongside Prof. Wong for more than a decade, I have been fortunate enough to observe the embodiment of his "Three Rs" - Respect, Resilience, and Resoluteness - in his work. He is not only my superior, but also a sagacious mentor, an inspiration and a trusted confidant.

 

In the article authored by Tang Ho Yeung et al., titled "Safety and efficacy of high-potency statin in Chinese patients with established cardiovascular disease," featured on page 70, it was reported that high-intensity statins demonstrated a greater reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with acute coronary syndrome. However, these statins were associated with a higher incidence of adverse effects compared to lower-intensity statins. Interestingly, the study found that neither statin intensity nor LDL-C goal attainment had significant effects on the occurrence or time-to-event of efficacy outcomes.

 

As we venture into this fresh chapter, we wish to extend our heartfelt appreciation to our readership for their unwavering support over the years. Your continued support is truly invaluable as we embark on this exhilarating digital journey. We firmly believe that transitioning to our online platform will not only enrich your experience but also present new avenues for growth. Furthermore, I would like to seize this opportunity to express my deep gratitude to the dedicated members of our Editorial Committee. Their tireless commitment and diligence have been instrumental in curating each issue. Additionally, I extend my sincere thanks to all the authors who have wholeheartedly supported the Journal. Your contributions have been greatly appreciated.

 

As always, you may provide suggestions and give feedbacks on any aspect of the Journal by contacting me or other members of the Editorial Committee. We would very much like to hear your thoughts on any part of the Journal and how we can further develop the Journal. But most importantly, how we can make it more appealing to you, our valued readers.

HKPharmJ

Tel: 23763090

Email: editor@hkpj.org

Room 1303, Rightful Centre, 12 Tak Hing Street, Jordon, Kowloon, Hong Kong